EichorEICHOR
Location: Fruitland Synced from ClinicalTrials.gov · August 08, 2026

Clinical studies recruiting near Fruitland

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Wi
Phase 2 · Saint Luke's Cancer Institute - Fruitland · National Cancer Institute (NCI) · NCT05564390Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
NA · Saint Luke's Cancer Institute - Fruitland · Alliance for Clinical Trials in Oncology · NCT07091617Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Phase 2/Phase 3 · Saint Luke's Cancer Institute - Fruitland · NRG Oncology · NCT05174169Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastati
Phase 3 · Saint Luke's Cancer Institute - Fruitland · Alliance for Clinical Trials in Oncology · NCT06931340ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathol
Phase 3 · Saint Luke's Cancer Institute - Fruitland · Alliance for Clinical Trials in Oncology · NCT06876714Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SL
Phase 3 · Saint Luke's Cancer Institute - Fruitland · National Cancer Institute (NCI) · NCT04269902Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and S
Phase 3 · Saint Luke's Cancer Institute - Fruitland · Canadian Cancer Trials Group · NCT06592924Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene M
Phase 2 · Saint Luke's Cancer Institute - Fruitland · SWOG Cancer Research Network · NCT05806515Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
Phase N/A · Saint Luke's Cancer Institute - Fruitland · Alliance for Clinical Trials in Oncology · NCT04242095Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carci
Phase 3 · Saint Luke's Cancer Institute - Fruitland · National Cancer Institute (NCI) · NCT05256225Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidin
Phase 2 · Saint Luke's Cancer Institute - Fruitland · National Cancer Institute (NCI) · NCT05554393Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Phase 2 · Saint Luke's Cancer Institute - Fruitland · SWOG Cancer Research Network · NCT05633615Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-S
Phase 3 · Saint Luke's Cancer Institute - Fruitland · National Cancer Institute (NCI) · NCT06498635Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Phase 3 · Saint Luke's Cancer Institute - Fruitland · ECOG-ACRIN Cancer Research Group · NCT04566328mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Neg
Phase 3 · Saint Luke's Cancer Institute - Fruitland · Alliance for Clinical Trials in Oncology · NCT05677490Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide,
Phase 3 · Saint Luke's Cancer Institute - Fruitland · National Cancer Institute (NCI) · NCT06058377A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V60
Phase 2 · Saint Luke's Cancer Institute - Fruitland · SWOG Cancer Research Network · NCT04511013Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Phase N/A · Saint Luke's Cancer Institute - Fruitland · ECOG-ACRIN Cancer Research Group · NCT04239573Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The Co
Phase 2 · Saint Luke's Cancer Institute - Fruitland · National Cancer Institute (NCI) · NCT05564377Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Phase 2 · Saint Luke's Cancer Institute - Fruitland · SWOG Cancer Research Network · NCT04205968Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Trea
Phase 2 · Saint Luke's Cancer Institute - Fruitland · National Cancer Institute (NCI) · NCT06317649A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Phase 3 · Saint Luke's Cancer Institute - Fruitland · National Cancer Institute (NCI) · NCT05675410Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (
Phase 2 · Saint Luke's Cancer Institute - Fruitland · National Cancer Institute (NCI) · NCT06126276Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Phase 3 · Saint Luke's Cancer Institute - Fruitland · ECOG-ACRIN Cancer Research Group · NCT04423211Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head
Phase 2 · Saint Luke's Cancer Institute - Fruitland · ECOG-ACRIN Cancer Research Group · NCT02734537Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had
Phase 2/Phase 3 · Saint Luke's Cancer Institute - Fruitland · SWOG Cancer Research Network · NCT06616584S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac
Phase 3 · Saint Luke's Cancer Institute - Fruitland · SWOG Cancer Research Network · NCT03418961Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
Phase N/A · Saint Luke's Cancer Institute - Fruitland · ECOG-ACRIN Cancer Research Group · NCT06002828S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic
NA · Saint Luke's Cancer Institute - Fruitland · SWOG Cancer Research Network · NCT03723928Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Phase 3 · Saint Luke's Cancer Institute - Fruitland · ECOG-ACRIN Cancer Research Group · NCT06475989
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.